- Products & Services
- Knowledge Base
ST. LOUIS, MO, April 07, 2018 /24-7PressRelease/ -- Acera Surgical, Inc. ("Acera") is a bioscience company commercializing a portfolio of fully synthetic, electrospun scaffolds for regenerative medical applications. Acera's products exhibit a structure similar to native extracellular matrix (ECM) and thus promote rapid and effective healing. The FDA cleared Acera's first product, Cerafix®, in March 2016 and its second product, Restrata™, in April 2017, both via 510(k), granting commercial access to markets exceeding $1.2B in revenue.
The OCMX™ is pleased to announce the listing of Acera Surgical Inc. to its online portal which offers Investors and Advisors the ability to participate in this opportunity.
The OCMX™ has spent considerable time completing its due diligence on Acera Surgical Inc. and concluded that there is indeed a tremendous opportunity for Investors and Advisors.
The OCMX™ noted that Acera Surgical Inc. exhibits the main components of any solid investment opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.
Dr. Matthew MacEwan – President / Chief Scientific Officer, Board Member | Dr. Matthew is responsible for research and product development, pre-clinical/clinical testing, regulatory compliance and clinical/medical affairs at Acera Surgical, Inc. Matthew is an MD/PhD Candidate at the Washington University School of Medicine in St. Louis, Missouri where he recently completed his PhD in Biomedical Engineering. Matthew has received multiple awards for his scientific and entrepreneurial work in the life science community, including the 2011 Olin Cup Award (Olin School of Business, Washington University), Grand Prize at the 2011 LES Global Business Plan Competition (International Licensing Executives Society), First Place at the 2011 I2P Global Competition (I2P, University of Texas), and Top 40 Under 40 in St. Louis (St. Louis Business Journal). Matthew graduated summa cum laude with a degree in Biomedical Engineering from Case Western Reserve University in Cleveland, Ohio with a specialization in polymer biomaterials / biomaterial biocompatibility.
Agnès Rey-Giraud – Chief Executive Officer, Board Member | Agnes is responsible for corporate strategy, corporate finance and business development at Acera Surgical, Inc. Agnès is a former Officer of Express Scripts, Inc., where she served in multiple roles in Product Development, Supply Chain, Corporate Strategy and International Operations. Agnès joined Express Scripts in 1999, and quickly became a driving force behind many of the company's key strategic initiatives and an influential player in the transformation of the company from a $4 billion enterprise to a $44 billion enterprise. In her most recent role as President, International Operations, Agnès led the company's movement into Asia. Agnès earned a Master of Science in Mechanical Engineering from Ecole Nationale d'Ingénieurs de Saint Etienne and a Master of Management in Operations Management from Ecole de Management de Lyon, both in France, as well as an MBA from the University of Chicago. Among numerous other awards and accolades, she is a 2011 St. Louis Business Journal Most Influential St. Louisan and a 2009 St. Louis YWCA Leader of Distinction.
Julie Cochran – Chief Operating Officer | Julie is responsible for product development, sales and marketing, business development and strategic planning, legal and regulatory affairs/compliance, finance, human resources and operations at Acera Surgical, Inc. Prior to joining Acera Surgical, Inc., Julie served multiple roles at Express Scripts, Inc., including Vice President of Strategic Planning, Vice President of Product Development, and Senior Director of e-business Product Management. Prior to Express Scripts, Julie was a consultant at McKinsey and Company, Inc., working with biotechnology, medical device, pharmaceutical and payer organizations. Julie graduated summa cum laude with a Bachelors of Science in Engineering in both Biomedical Engineering and Electrical Engineering from Duke University and earned an MBA from the Stanford Graduate School of Business.
ABOUT THE OCMX™
The OCMX™ is literally changing how companies and investment funds generate exposure in the marketplace and raise funds as we know it. The OCMX™ serves both public and private companies along with investment and mutual funds which need to raise additional funds or gain significant market exposure. It does this by way of connecting the relevant companies, funds, investors, and advisors all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.
The OCMX™ connects investors and advisors directly with companies and investment funds seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors. The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
# # #